)
Visual
earnings real time
NeuroScientific Biopharmaceuticals
NeuroScientific Biopharmaceuticals (NSB) investor relations material
NeuroScientific Biopharmaceuticals Investor Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor Update summary13 Nov, 2025
Strategic evolution and technology acquisition
Acquired the patented STEMsmart stem cell platform, pivoting focus to address unmet needs in inflammatory, degenerative, and autoimmune conditions, with initial emphasis on Crohn's disease.
New leadership and expertise brought in, including a new CEO and Chief Medical Officer, to drive the new strategy.
Early-stage clinical data supports efficacy, with a 78% response rate and over 50% remission in refractory Crohn's patients from previous trials.
Clinical development and special access program
Special access program launched in Australia for fistulizing Crohn's disease patients with no other treatment options; first four patients treated, aiming for up to 12.
Results from the first four patients expected in January, with full program results by mid-2026.
Data from this program will inform the design and execution of a phase two clinical trial in Australia and the US.
Manufacturing and partnerships
Manufacturing tech transfer to Qiagen, a leading contract manufacturer, to scale production and de-risk supply for clinical trials and commercialization.
Qiagen's experience with TGA and international standards strengthens regulatory and supply chain reliability.
How SAP results inform Phase 2 trial design?
StemSmart's differentiation vs Mesoblast?
Prioritize next indication after Crohn's?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- EMCURE
Q3FY26 revenue rose 20% YoY, PAT up 48%, with margin gains and robust global growth. - 500870
Record revenue and 8% volume growth in FY25, with robust margins and strong dividend payout. - SOI
Q3 revenue €160m, up 18% sequentially, Edge & Cloud AI up 27%, Q4 set for 20% growth. - IFX
Q1 2026 revenue rose 7% year-over-year, driven by AI demand and increased investments. - ELS
2025 revenue soared 11x to $23M, with strong cash, major contracts, and a robust 2026 outlook. - V2RETAIL
Q3 FY26 saw 57% revenue and 99% PAT growth, with robust expansion and capital infusion. - UBSG
Net profit surged 53% in FY25, with integration and cost savings driving strong results. - 524348
Q3 FY26 revenue up 8% and PAT up 58%, with margin recovery and new projects ramping up. - BOTX
Record gold output and profit, with investments driving strong growth outlook for 2026. - BAJAJFINSV
Q3 FY26 profit was flat at ₹2,229 crore as strong growth was offset by one-time charges.
Next NeuroScientific Biopharmaceuticals earnings date
H1 202625 Feb, 2026
NeuroScientific Biopharmaceuticals
Next NeuroScientific Biopharmaceuticals earnings date
H1 202625 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
NeuroScientific Biopharmaceuticals Limited is a biotechnology company focused on researching and developing therapies for neurodegenerative diseases and neurotrauma. The company’s work centers on novel peptide-based treatments aimed at conditions such as Alzheimer’s disease, multiple sclerosis, and other neurological disorders that involve degeneration or damage to nerve cells. The company is headquartered in Perth, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage